For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was $3.9 for the day, down -1.27% from the previous closing price of $3.95. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 0.7 million shares were traded. CRVS stock price reached its highest trading level at $3.93 during the session, while it also had its lowest trading level at $3.79.
Ratios:
Our analysis of CRVS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 02, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 27 ’25 when ORBIMED ADVISORS LLC sold 1,176,332 shares for $4.16 per share. The transaction valued at 4,891,894 led to the insider holds 7,165,006 shares of the business.
Thompson Peter A. sold 1,176,332 shares of CRVS for $4,891,894 on Jun 27 ’25. The Director now owns 7,165,006 shares after completing the transaction at $4.16 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRVS now has a Market Capitalization of 300746944 and an Enterprise Value of 265399552.
Stock Price History:
The Beta on a monthly basis for CRVS is 0.41, which has changed by 1.1546962 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, CRVS has reached a high of $10.00, while it has fallen to a 52-week low of $1.75. The 50-Day Moving Average of the stock is 1.71%, while the 200-Day Moving Average is calculated to be -26.10%.
Shares Statistics:
CRVS traded an average of 1.17M shares per day over the past three months and 1544380 shares per day over the past ten days. A total of 68.17M shares are outstanding, with a floating share count of 56.46M. Insiders hold about 26.78% of the company’s shares, while institutions hold 28.96% stake in the company. Shares short for CRVS as of 1749772800 were 7939714 with a Short Ratio of 6.77, compared to 1747267200 on 7231927. Therefore, it implies a Short% of Shares Outstanding of 7939714 and a Short% of Float of 12.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Corvus Pharmaceuticals Inc (CRVS).The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.09 and -$0.18 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.56, with 5.0 analysts recommending between -$0.41 and -$0.64.
